What We're Reading: Page 80
Industry reads hand-picked by our editors
Aug 08, 2023
-
The Atlantic
There’s a New Drug for Eczema—Actually, a Ton of New Drugs
-
Financial Times
Meta disbands protein-folding team in shift towards commercial AI
-
Fierce Biotech
20 years in, Singapore still searches for its biotech success story
-
Bloomberg
Elon Musk’s Neuralink Raises $280 Million to Develop Brain Implants
Aug 07, 2023
Aug 04, 2023
-
Bloomberg
Murder, Money and the Battle for a Pharmaceutical Empire
-
STAT
ProMED, an early warning system on disease outbreaks, appears near collapse
-
Reuters
Mesoblast shares tank after US FDA rejects cell therapy for children
-
The Wall Street Journal
AI-Generated Data Could Be a Boon for Healthcare—If Only It Seemed More Real
Aug 03, 2023
-
The New York Times
Amid Signs of a Covid Uptick, Researchers Brace for the ‘New Normal’
-
Bloomberg
China Drug-Price Negotiations Offers Glimpse Into Future for Companies in US
-
The Financial Times
Lawsuit alleges blockbuster weight-loss drugs cause ‘stomach paralysis’
-
Fierce Biotech
It’s Goose Data’s (online) world, and biotechs are just sitting ducks
Aug 02, 2023
Aug 01, 2023
-
JAMA
Are New Alzheimer Drugs Better Than Older Drugs?
-
The Wall Street Journal
Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
-
Healthcare Dive
CVS to lay off 5K employees amid cost pressures
-
The Baltimore Sun
Family of Henrietta Lacks settles HeLa cell lawsuit with biotech giant, lawyer says
Jul 31, 2023
-
Reuters
Drugmakers go under the skin, skirting early US Medicare price negotiations
-
San Francisco Business Times
FibroGen limits rare-disease drug’s access after clinical trial failure. Some parents say it was saving their kids’ lives
-
The Washington Post
Lifesaving HIV program faces a new threat: U.S. abortion politics
Previous
